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1. Introduction
In this chapter, we briefly summarize the concept of analytical methodologies used for de‐
tecting, measuring, and/or monitoring in public health research. Additionally, this chapter
describes in silico ADME, ADMET and ADME/Tox approaches or models relevant to analyt‐
ical methodologies for public health researchers or practitioners.
Recently, adopted technologies to cope with this type of scientific demand in terms of drug
development and testing are the applications of in silico techniques used in pharmaceutical
companies in the process of drug discovery (Ndibewu et al., 2012; Vallero, 2012; Lipinski et
al., 1997; Leeson & Springthorpe, 2007). Two fast growing examples involve the use of
cheminformatics (also known as chemoinformtaics) and chemical informatics which is the
use of computer and informational techniques, applied to a range of problems in the field of
chemistry (Langdon et al., 2011; Brown, 2011). These in silico techniques are employed in
pharmaceutical companies in the process of drug discovery (Lipinski, 2004). These methods
can also be used in chemical and allied industries in various other forms (Pradeep, 2009).
Combined with the accuracy of data obtained with validated analytical methods, this en‐
compasses the mixing of those information resources necessary to transform data into infor‐
mation and information into knowledge for the intended purpose of making better decisions
faster in the area of drug lead identification and optimization. The outcome is clearly the ef‐
ficiency in public health research and the beneficiary is mankind. In the section that follows,
we briefly summarize in silico pharmacokinetics, widely designated as ADME approaches or
models relevant to analytical methodologies for public health researchers or practitioners
(Yamashita & Hashida, 2004). Pharmacokinetics is the study of the time course of a drug
within the body and incorporates the processes of absorption, distribution, metabolism and
© 2013 Ndibewu and Ngobeni; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
excretion (ADME) (Van de Waterbeemd & Gifford, 2003). The extent of distribution will de‐
pend on the structural and physicochemical properties of the compound (Fig. 1).
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Figure 1. ADME flow chart showing volume of distribution (Vd): is a theoretical concept connecting administered dose
with actual initial concentration (Co) present in circulation, Vd = Dose/Co; Unbound volume, Vdu = Vd/fu, where fu is the
fraction of unbound; Clearance (Cl) of the drug from the body mainly takes place via the liver and the kidney; Bioavail‐
ability is given by area under the curve (AUC) = F x Dose/Cl; Half-life (t1/2) is the time taken for a drug concentration in
plasma to reduce by 50% (is function of the clearance and volume of distribution, and determines how often a drug
needs to be administered (t1/2 = 0.693Vd/Cl) (Van de Waterbeemd & Gifford, 2003).
Figure 2 shows a simple ADME decision-making flow sheet which will incorporate predic‐
tors for volume of distribution, oral bioavailability, half-life (t1/2), distribution\protein bind‐
ing module including percentage plasma protein binding values (%PPB) and drug affinity
constant to human serum albumin represented by log KaHSA constants. The adaptability of
this simple form has continuously refine existing models by building on larger and higher-
quality data sets crucial to the success of the in silico approaches as grouped by Van de Wa‐
terbeem and Gifford (2003) in the form of problem areas for which predictive models could
be helpful (Fig. 2). And during these past few years, the range of models have further ex‐
panded to include, for example, models for various transporters, metabolism by non-P450
enzymes, plasma protein binding, and so (Lu et al., 2003; Ekins et al., 2001).
Figures 2a and 2b outline the parameters in the prediction of a safe drug given in acceptable
dose, which it is ultimately hoped will be reliably obtainable from molecular structure and
appropriate descriptors using a suite of predictive models. This expression had earlier been
made clear by Japertas and coworkers (2011).
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Figure 2. a. An analysis of the crucial ADME processes for which predictive models are available or are being devel‐
oped (Carlson & Segall, 2002). b. Prediction paradigm ranging from models for simple physicochemical properties (H-
bonding capacity, Molecular mass, Solubility and lipophilicity (logD)) to models for ADME properties (% drug
absorbed & bioavailability, clearance, volume of distribution and half-life (t1/2)) to complex endpoints (binding (IC50), to
molecular target of new drug and its required dose and toxicity potential (Waterbeemd & Gifford, 2003). c. The evolu‐
tion of drug discovery and the changing role of ADME studies I (Waterbeemd & Gifford, 2003)
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In figure 2c (Waterbeemd & Gifford, 2003), the form a depicting the classical project-collabo‐
ration approach between chemistry, biology and drug metabolism (ADMES) groups in the
1990s is shown to b which is a much more automated world at the start of this millennium in
which combinatorial chemistry (CombiChem), high throughput screening and ADME studies
are linked together in a streamlined fashion.
It should be noted that all three activities shown in figure 3 can even be carried out by sepa‐
rate companies of research units or even researchers in health departments or for health in‐
terest. A good example is the Medical Research Council (MRC) of South Africa which
supports unit health research projects towards a nationally planned and prioritized health
sectors. Furthermore, the wide introduction of in silico and high-speed in vivo methods
could redefine the traditional meaning of ADME to Automated Decision-Making Engine. To
reflect, one sees that considerable effort has equally been devoted into the development of in
silico models for the prediction of oral absorption (Veber et al., 2002; Agoram et al., 2001;
Parrott & Lavé, 2002; Yu et al., 2000). This range from the simplest models based on a single
descriptor, such as log P or log D, or polar surface area, which is a descriptor of hydrogen-
bonding potential to combo or meta- or QSAR models.
2. Analytical methods in health research
As analytical methods become increasingly sophisticated and capable for the detection of
each component in a sample (Barnes & Dourson, 1988), including biological systems (Kote-
Jarai et al. 2011), it is critical to separate and quantify them. Methods such as mass spectrom‐
etry (MS) and high performance chromatography (HPLC) routinely ensure these in many
laboratories around the world (Thorp et al., 2011). HPLC instrumentations provide crucial
analytical data (Beitler, 1995) used to calculate or predict drug’s affinity constants (log KaHSA)
(Packard et al., 1996; Endo et al., 1982). For nearly half a century, analytical and testing
methods as opposed to empirical approaches have played a key role in the identification of
key diseases causative toxins (Barnes & Dourson, 1988; Bathija, 2003) and drug-like com‐
pounds to cure them (Kote-Jarai et al., 2011; Moore & Carpenter, 1999).
In this process, as tons of data are being produced with the analytical chemists struggling to
make sense out of the bunch, the health researcher and health practitioners are faced with a
constant task to make better and faster decisions in the area of disease treatment and pre‐
vention based on laboratory results. In the midst of all this, there is the requirement not only
to produce efficient drugs, in enough quantities, to cure diseases but their development at
the pace at which pandemics are spreading around the globe is also required, for example,
cancer and HIV & AIDS.
As far as the identification of data needs is  crucial  in clinical  laboratories,  the quest  for
methods to determine biomarkers of exposure and effect of diseases in the public health is
also growing fast. Hence, analysis of metabolites of drugs in humans or animals can pro‐
vide a biomarker of exposure that is sensitive to low levels of exposure and correlates well
with  exposure  concentrations.  Methods  for  determining  biomarkers  of  exposure  in  hu‐
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mans are needed to determine background levels in the population and levels at which bi‐
ological  effects  occur.  For  example,  Abdel-Rahman  et  al.  (1980a  &  1980b)  developed  a
method  to  quantitatively  and  qualitatively  measure  the  metabolites  of  chlorine  dioxide
(e.g.,  ClO2-,  and  ClO-)  in  biological  fluids.  These  biomarkers  may  be  used  to  indirectly
measure chlorine dioxide exposure.
In the absence of sensitive and reliable methods for determining diseases vector-borne me‐
tabolites and biomarkers of exposure, mechanistic models of tissue distribution of drug
compounds have been used (Rowley et al., 1997) to assess levels at which biological effects
occur in the population and mitigate disease occurrence. Poulin et al. (Poulin & Theil, 2002;
Poulin & Krishna, 1995) developed tissue composition-based equations for calculating tis‐
sue-plasma partition coefficients (Pt:p).
The following expressions are used (equations 1 and 2) (Yamashita & Hashida, 2004):
:
:
:
( 0.3 ) ( 0.7 )
( 0.3 ) ( 0.7 )
o w nlp php wt pht Up
t pnonadipose
o w nlp php wp php Ut
P V V V V fP xP V V V V f
+ + += + + + (1)
*
:
: *
:
( 0.3 ) ( 0.7 )
1( 0.3 ) ( 0.7 )
vo w nlt pht wt pht Up
t p adipose
vo w nlp php wp php
D V V V V fP xD V V V V
+ + += + + + (2)
Po:w is the n-octanol:buffer partition coefficient of non-ionized species at pH 7.4.
D*vo:w is the olive oil:buffer partition coefficient of both the nonionized and ionized species
at pH 7.4, V is the fractional tissue volume content of neutral lipids (nl), phospholipids (ph),
and water (w), t is the tissue, p is the plasma and fu is the unbound fraction.
These equations are based on the assumption that each tissue and plasma is a mixture of lip‐
ids, water and plasma proteins in which the drug can be homogeneously distributed.
The first term of these equations is based on the drug Lipophilicity-hydrophilicity balance
of tissues and plasma due to their lipid and water contents, while the second term of the
equation considers the binding to common proteins present in plasma and plasma intersti‐
tial space.
3. Use of In-silico techniques and chemical informatics in health research
Even though disease mapping has been done for over a hundred years, historically, the focus
in health research has been on person and conventional medicinal chemistry targeting specif‐
ic disease treatment with little regard for the implications of de novo molecular design costs.
Also, the need for high throughput screening in drug discovery research for public health in‐
terest has surfaced as a top priority in the last decade (Norris et al., 2000; Green et al, 1974).
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However, the testing of much lead drug-like candidates often fails because of unsatisfactory
ADME properties (Zmuidinavicius et al., 2003). In handling this challenge, ADME studies
employing in silico techniques to improve the rate of success in the more costly downstream
stages of drug development before clinical trials has gain tremendous interest in public health
research methodologies. In this light, in silico ADME studies use various models developed
for predicting ADME properties of compounds from their chemical structures and integrat‐
ing them to simulate the kinetics at the organ or body levels Carlson & Segall, 2002; Podlogar
et al., 2001; Ekins et al., 2001). Data-based approaches such as quantitative structure-activity
relationship (QSAR) (Zhaou et al., 2001, Yoshida & Topliss, 2000), similarity searches, 3D-
QSAR (Jones et al., 1996) and structure-based methods such as ligand-protein docking and
pharmacophore modeling are amongst approaches currently used. In addition, several meth‐
ods of integrating ADME properties to predict pharmacokinetics at the organ or body level
have been studied (Agatonovic-Kustrin, 2001; Van de Waterbeemd, 2001; Ho et al., 2000; Jaco‐
by et al., 2009; Lave et al., 1999). All these effort is to reduce the risk of late-stage attrition of
drug development and to optimize screening and testing by looking at only the promising
compounds. Recently, researchers have equally develop keen interest in de novo molecular de‐
sign (Good et al., 1995; Clark et al., 1995), predictive modeling, graph theory, molecular simi‐
larity and diversity, virtual ligand docking, scaffold hopping (Langdon et al., 2010), multi-
objective optimization Nicolaou et al., 2007), molecular descriptors, bioisosteric replacement,
machine learning and evolutionary algorithms (Gillet, 2008).
In the last decade, a wide variety of descriptors used in QSAR studies have been developed
(Khan et al., 2009; Miners et al., 2006). A subset of these descriptors is potentially useful for
predicting ADME properties. Many QSAR studies on BBB permeation of drugs have been
published recently. In the big junk of these works (Wichmann et al., 2007; Zhao et al., 2007;
Cuadrado et al., 2007; Katritzky et al., 2006; Garg & Verma, 2006; Hemmateenejad et al.,
2006; Narayanan & Gunturi, 2005) experimental data are represented as logBB constants or
as qualitative (binary) index subdividing all compounds into ‘CNS positive’ and “CNS neg‐
ative” classes according to presence or lack of central nervous system (CNS) activity. Table 1
summarizes the most notable QSAR models (logPS) representing blood/brain partitioning
coefficients at equilibrium conditions (logBB)( Goodwin & Clark, 2005; Abbott, 2004) show‐
ing that typical data sets involved only 20-30 compounds.
LogPS is based on in vivo kinetic permeability measurements using intravenous administra‐
tion (Oldendorf, 1971), brain uptake index (Bickel, 2005; Oldendorf, 1971) and in situ perfu‐
sion in rat or mouse (Bickel, 2005; Dagenais et al., 2000; Takasato et al., 1984;). Where, P (cm
s-1) is observed permeability across BBB, whereas S (cm2/g) is surface area of brain capillary
endothelium which equals to ~ 100 – 130 cm2 in rats (Abraham, 2004; Bodor & Buchwald,
1999). PS product can be calculated from Kety-Renkin-Crone equation of capillary transport
(Kin = F. (1- e-PS/F)), and by its physical meaning, PS is equal to the unidirectional influx rate
constant (Kin) corrected for cerebral blood flow (F). Earlier attempts of logPS prediction were
largely restricted by the lack of high quality data. A subset of statistical techniques can deal
with larger sets of molecular descriptors aimed at finding relationships or patterns in data
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sets. For examples, multiple linear regressions (MLR) and partial least square (PLS) (Norind‐
er & Österberg, 2001).
References Descriptors N R2 RMSE
Levin19 Log(P.MW-1/2) 22 0.83 -
Abraham and coworkers10,24 Solvation parameters (A, B, E, S, Vx) 18 0.95 0.48
30 0.87 0.52
Bodor and Buchwald11 LogP(logD) 58 0.90 0.62
Liu et al.5 LogD, PSA, vsa base 23 0.74 0.50
Luco and Marchevsky25
(review of earlier studies)
LogP, different MW functions 7-37 0.80-0.96 -
This literature LogP, HD, HA, Vx, ion fractions (pKa
function) 125
a 0.84 0.48
53b 0.82 0.49
aTraining set; bValidation set.
Table 1. Summary of QSAR Models for Predicting LogPS (Lanevskij et al., 2008)
These illustrations show how in silico chemistry or cheminformatics and high-throughput
screening have increased the possibility of finding new lead compounds at much shorter
time periods than conventional medicinal chemistry. With judicious selection of lead com‐
pounds and constant monitoring of physical properties (especially Lipophilicity (equation 1)
or other major physchem parameter) during optimization, medicinal chemists have an op‐
portunity to help alleviate the appalling attrition rates, estimated at 93–96% (Norris et al.,
2000) in clinical drug development (Bhal et al.,. This means that physicochemical properties
in small-molecule drug discovery are completely under the control of medicinal chemists
and can easily be calculated before chemical synthesis. It is, however, important to empha‐
size here that when interpreting results from prediction models, that the predictions are on‐
ly as good as the dataset used to create the model. So when we calculate a prediction, if the
training set does not contain chemical structures that are similar to the particular compound
in question, the predicted result may not be reliable, regardless of the actual result of the
prediction.
From various literature sources (Bhal, 2007; Sazonovas et al., 2010), it is reported that ADME
and toxicity prediction models can be a valuable part of many different research workflows,
including virtual screening, metabolite identification, impurity analysis and chemical safety,
reliability index (RI) value (0 – 1) in addition to the predicted probability result (Japertas et
al., 2010) which is an indicator of how well spatial chemical space around a particular com‐
pound is represented within the training set of the model (Fig. 3)
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 Figure 3. Model applicability domain versus proprietary chemical space, predicted using ACD/LogD Suite (Bhal &
Coworkers, 2007)
The development of in silico technologies or chemical informatics over the last 20 years has,
thus, provided a more powerful and rapid ability to examine clinical decision-making and
answers to critical public research health issues based on scientifically validated models
from an un biased an empirical question based on a minimally biased appraisal of all the
relevant empirical studies. This, in turn, has fostered the discussion of policy of drug discov‐
ery relevant to health issues as well as health services and planning, in conjunction with the
use of clinical investigations and disease surveillance. Such reviews aim to improve ethically
relevant decisions in public healthcare research or policy. With this in mind, identification of
a lead compound or biochemical starting point for a drug discovery program has been high‐
lighted recently as a critically important activity, reflected by lead generation strategies be‐
ing widely implemented in the pharmaceutical industry (Jupertas, 2007).
For a more robust process, calculated quantitative parameters will provide further informa‐
tion though slightly different from the core predictive pharmacokinetic data. These parame‐
ters show great inter relation. Such parameters include the drug’s affinity constants (log
KaHSA) to human serum albumin (the major carrier protein in plasma). Experimental data
come from direct chromatographic determination of binding strength to that particular pro‐
tein. These parameters are usually calculated as follows (Bhal et al. 2007):
[ ]log log .[ [ ]]
HSA
a
LAK L A
æ ö= ç ÷è ø (3)
Where [LA] is the concentration of ligand bound to albumin, [L] is that of free ligand, and
[A] is the concentration of free albumin which, estimated at ~ 0.6 mM in human plasma.
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%PPB values represent the overall fraction of drug bound in human plasma, i.e. accounts for
interactions with different proteins: albumin, α-1-acid glycoprotein, liproteins, SHBG, trans‐
ortion, etc. In vitro measurements of the extent of plasma protein binding usually involve
equilibrium dialysis, ultrafiltration or ultracentrifugation methods. The supplementary dis‐
tribution/Vd module calculates apparent volume of distribution of drugs in human body ex‐
pressed in litres per Kg body weight (L/Kg). This expression is given as: %PPB = (1-fu) x
100%, Where fu is a fraction of free (unbound) drug in plasma (0 -1). Note that predictive
models for %PPB and logaHSA are derived using GALAS (Global, Adjusted Locally Accord‐
ing to Similarity) modeling methodology consisting of global (baseline) statistical model
(based on PLS with multiple bootstrapping, using a predefined set of fragmental descrip‐
tors), and local correction to baseline prediction (based on the analysis of model perform‐
ance for similar compounds from the training set = self-training library). Because of the
percentage (%PPB) scale platform of the overall protein binding in plasma, values are linear‐
ized prior to modeling and converted to apparent serum affinity constants, log Kapp, the main
parameter used in modeling. With this, final prediction can be converted back to %PPB us‐
ing the following expression (Bhal et al., 2007):
log% 100%1 log
app
app
KPPB xK= + (4)
To illustrate the performance of %PPB and logaHSA models, validation set compounds within
Model Applicability Domain (MAD) (RI ≥ 0.3) is taken from Bhal et al. (2012) and shown in
figures 4. In equation (y), the local part of the model provides the basis for estimating relia‐
bility of prediction by means of calculated Reliability Index (RI) values that range from 0 – 1.
0 means unreliable prediction and 1 fully reliable or ideal prediction. The RI values can also
be used for interpreting prediction results, for example in setting the cut-off point (RI = 0.3),
meaning that if compound falls outside of the MAD, the respective prediction should be to‐
tally discarded from further analysis irrespective of %PPB and logaHSA.
Figure 4. Predicted versus observed %PPB and logaHSA values for validation set compounds (ACD/LogD Suite).
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Figure 5. Predicted versus experimental values of logLD50 (with a very high RI > 0.75) %PPB and logaHSA values for vali‐
dation set compounds (Bhal et al., 2012).
In figures 5 and 6, both models produce highly accurate results, while even better statistical
characteristics are observed if only predictions of moderate and high reliability index are
considered.
In order to understand the behavior of drug compounds in the real world, Bhal et al. (2012)
has used ACD/Predictors such as logP, logD, solubility, and pKa to evaluate and predict the
likely behavior of 5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine (Fig. 7), a compound prior
to its synthesis. Lipophilicity is represented by the descriptors logP (also known as Kow or
Pow) and logD, and is used, for example, to help predict in-vivo permeability of active com‐
pounds in drug discovery and the behavior of compounds in many other areas of health re‐
lated research. The partition coefficient, P, is a measure of the differential solubility of a
compound in two immiscible solvents and the most commonly used commonly used sol‐
vent system is octanol-1-ol/water.
Figure 6. Chemical structure of 5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine, A
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The P descriptor is a lipophilicity descriptor for neutral compounds, or where the com‐
pounds exist in a single form.
Partition coefficient , p = Compound octanolCompund water  and LogP = log10(Partition Coefficient)
LogP = 1 can be explained as a ratio of 10 :1 organic:aqueous phase.
For ionizable solutes, the compounds may exist as a variety of different species in each
phase at a given pH. D, typically used in the logarithmic for (loD) representing the distribu‐
tion coefficient which is the appropriate descriptor for ionizable compounds since it is a
measure of the pH-dependent differential solubility of all species in the octanol/water sys‐
tem (Levin, 1980).
Distribution coefficient , D = ∑ Microspecies octanol∑ Microspecies water .
Bhal (2012) used methylamine to illustrate the difference between these two descriptors as
follows: MeNH3+ ⇌  MeNH2 + H+, meaning that,
PMeN H 2 =
MeN H 2 octanol
MeN H 2 water
 and/or PMeN H 3+ =
MeN H 3+ octanol
MeN H 3+ water
.. So, keeping the definition of D above in
mind, we can write the expression of D as:D = MeN H 2 octanol + MeN H 3
+ octanol
MeN H water + MeN H 3+ water
.
To accurately predict a compound’s lipophilicity based on predicted molecular physical
properties, it was imperative that the author applied the correct descriptor in an appropriate
manner. In this context, logD instead is used in lieu of logP as the use of the latter to address
lipophilicity concerns by drug research and manufacturing companies in the past (around
1980’s and 90’s) had resulted in incorrect conclusions for ionizable compounds. A good ex‐
ample would be to reproduce data generated by the previous author employing ACD/LogD
in his application to discuss the significance of applying logD instead of logP using drug
discovery as an example where lipophilicity is correlated with in vivo permeability. Using
the sample molecule in figure 6 (5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine), data pre‐
sented in table were calculated.
pKa Ionization centre
4.8 Pyridine
10.9 Piperidine
Table 2. pKa values of 5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine (Bhal et al., 2012)
The pH dependence of logD for this sample molecule (5-Methoxy-2-(1-piperidin-4-ylprop‐
yl)pyridine) is shown in figure 7 showing a plot of logD versus pH, while figure 8 displays
the changing ionic forms of molecule A.
Looking at the plot in figure 8, and according to Bhal el al. (2012), we can confirm that ioniza‐
tion of the compound greatly affects octanol-water partitioning and that lipophilicity cannot
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be simplified to a constant. This is very so as lipophilicity of the compound is low below pH
12 when the majority of the compound exists in an ionized form. This would definitively be
contradictory, of course, if logP was examined alone (Predicted logP is 2.7 ± 0.3 by author for
comparison sake).
Figure 7. The logD curve of 5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine (ACD/LoD Suite), Bhal et al., 2012)
The author concludes that the negative values of logD (-1.44 to 0) in the physiologically rele‐
vant pH range (pH 1–8) lead us to conclude that this compound would be more susceptible
to higher aqueous solubility and of lower lipophilicity in the body. As a result we would
expect membrane permeability to be poor. Also, it is true as seen from graph in figure 8 the
neutral form of molecule A is almost non-existent at physiologically relevant pH (1–8). This
neutral form possibly dominates at ~pH 13. Conclusively, compound A is highly associated
with the lipid phase (>30 fold affinity for octanol over water), and thus will likely permeate
biological membranes spontaneously.
Figure 8. A graph illustrating the changing ionic forms of 5-Methoxy-2-(1-piperidin-4-ylpropyl)pyridine with pH (Bhal
et al., 2012)
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Figure 9 shows a schematic representation of the changing pH environments that an orally
administered compound is likely to encounter in the gastrointestinal (GI) tract. From fig‐
ure 9, we can observe that there is, thus, no constant pH in the body and it is therefore es‐
sential that we consider an appropriate pH when predicting the in vivo behavior of a drug
candidate.
Figure 9. The pH environment of the human gastrointestinal tract (Bhal et al., 2012)
4. Implications of analytical methods and in-silico techniques in public
health
The outcomes from a global network on the development of standardized analytical meth‐
ods for the public and environmental health directly impacts on the quality of health of
mankind worldwide. High quality data necessitates the development of harmonized study
approaches and adequate reporting of data (Bouwmeester et al., 2011).
Priority public health scale can only be based on well-characterized dose-response relations
derived from a systematic study of the bio-kinetics and bio-interactions of drugs or drug-
like molecules at both organism and (sub)-cellular levels using validated analytical methods
and pharmacokinetic studies. The ADME (absorption, distribution, metabolism and excre‐
tion) and toxicity effects is crucial to declare a particular molecule safe for the treatment of a
particular disease and often clinical trials to arrive at a conclusive release of a new drug very
costly, sometimes in the range of millions of dollars covering the cost of fundamental re‐
search through clinical trials or testing to manufacturing. Multiple content databases, data
mining and predictive modeling algorithms, visualization tools, and high-throughput data-
analysis solutions are being integrated to form systems-ADME/Tox (Ekins et al., 2005). More
so, Ekins and co-authors (2005) reported that the functional interpretation and relevance of
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complex multidimensional data to the phenotype observed in humans is the focus of current
research in toxicology.
In fact, increased effort is needed to develop and validate analytical methods to determine
ADMET effects in complex matrices such as the human body. This implies the use of vali‐
dated analytical methods and in-silico chemistry to reduce time and cost at developmental
stage. In addition, this would allow for systematic study of sets of drug-like molecules’ reac‐
tivities with specific aim to generate a data set which would allow the establishment of
dose-response relations. This approach is commonly referred to as quantitative structure-ac‐
tivity relationship (QSAR) and has a practical implication in the process of in-silico algo‐
rithms optimizations. A more general but direct implications of analytical methods and in-
silico techniques in public health is that international cooperation and worldwide
standardization of terminology, reference materials, models and protocols are needed to
make progress in establishing lists of essential globally acceptable drug formulation meth‐
ods, clinical trials, quality control and assurance. In this way, traditional pharmacopeia and
those exploiting natural biodiversity can benefit from proven methods at the grassroots’ lev‐
els, especially in developing countries.
Metabolomics,  metabonomics,  proteomics,  pharmacogenomics  and  toxicogenomics,  are
groups of latest experimental approaches that are combined with high-throughput molecu‐
lar screening of targets to provide a view of the complete biological system that is modulat‐
ed by a compound with direct or indirect implications of analytical methods and in-silico
techniques development for application in the public health sector (Ekins et al., 2005). In
conclusion,  it  is  widely  recognized  in  industry-orientated  research  and  development  of
APIs  (active  pharmaceutical  ingredients)  that  predicting  or  determining  the  ADME/Tox
properties of molecules would help to prevent failure of many of the compounds targeted
before they reach the clinic. Many authors (Bhal et al., 2012; O’Donnell et al., 2012; Ndibe‐
wu et al., 2012; Thorp, 2011; Ekins et al., 2005) agree that this has, undoubtedly, been as a
result of considerable research into developing better in-silico, in vitro and in vivo methods
and models.
5. General conclusion
Driven by the changes in the working paradigm in the pharmaceutical and biotechnology,
and  now  in  environmentally  health-related  research,  in-silico  approaches  will  inevitable
find their  place.  Some insilicoids have even mentioned that  this  approach will  save the
world. This is, probably, owing to the gains recorded in terms of cost reduction and effi‐
ciency for early stage drug discovery research to the point of manufacturing of some im‐
portant drugs or vaccines to which the future of mankind mercilessly rely like terminal
illnesses such as cancer or HIV-AIDS. All these diseases are unquestionable public health
pandemonium requiring quick systematically robust  holistic  research approaches to halt
their effects on human evolution.
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Conclusively, ADMET data is tackled in three ways, namely: first, a variety of in vitro assays
are further automated through the use of robust laboratory integrated system (LIM); second‐
ly, in silico models are used to assist in the selection of both appropriate assays, as well as in
the selection of subsets of compounds to go through these screens. And thirdly, predictive
models have are then developed that might ultimately become sophisticated enough to re‐
place in vitro assays and/or in vivo experiments. So, the need for ADMET information should
start with the design of new compounds. Finally, this information shall influence the deci‐
sion to proceed with synthesis either via traditional medicinal chemistry or combinatorial
chemistry strategies. Although, it but obvious that at this point computational approaches
are the most appropriate option to get this information, we should never, however, forget
that predictions can be imperfect if flawed with errors. So, optimization should be the way
forward once a lead compound is obtained and further optimized using more robust mecha‐
nistic models towards clinical trials before final manufacturing and authorization for ab‐
sorption as a public health drug.
6. Recommendations
Since most models are rule-based and may use descriptors that are not easily understood by
the chemist or not easily translated into better molecular structures, it is important to con‐
stantly train models of datasets. A combo approach, combining first generation (basic pre‐
dictive descriptors) and second generation (meta-models) computational ADMET
technologies would be the best way to go.
To then get value for your money, it is clearly demonstrated that ADME predictive tools is
imperative, nowadays, in the health research programs in order to cut costs and propose re‐
liable lead drug-like compounds. It is though highly desirable and recommendable to add
in-house data in the prediction models whenever available. Sensitive and reliable high
throughput instrumentations are a prerequisite in generating in-house analytical data neces‐
sary for efficient and useful predictive processes. Training data sets in models would be an
added advantage for a wide range of investigations in health related research.
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